Surgery Websites
Transplant Surgery »  Meet the Team »  Hepatology »  Neil Mehta, M.D.
Neil Mehta, M.D.

Neil Mehta, M.D.

Assistant Professor of Medicine
General Hepatology and Liver Transplantation
Department of Medicine

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357     
San Francisco, CA 94143-0358
(415) 476-6422 - Phone
(415) 476-0659 - Fax
Open Popup

Johns Hopkins University, BA, Neuroscience, 1998-2002

University of California, San Francisco School of Medicine, MD, 2002-2006

  • Hospital of the University of Pennsylvania, Intern, Internal Medicine, 2006-2007
  • Hospital of the University of Pennsylvania, Resident, Internal Medicine, 2007-2009
  • University of California, San Francisco, Fellow, Gastroenterology, 2009-2012
  • University of California, San Francisco, Fellow, Transplant Hepatology, 2012-2013
  • American Board of Internal Medicine
  • American Board of Internal Medicine - Gastroenterology
  • American Board of Internal Medicine - Transplant Hepatology
  • UCSF Liver Center
  • Cardiopulmonary complications of chronic liver disease
  • Hepatocellular carcinoma (HCC)
  • Liver injury and repair (Liver transplantation)
  • Liver transplantation outcomes including expanded criteria liver transplants

Dr. Neil Mehta is a general and transplant hepatologist, specializing in treating patients with hepatocellular carcinoma (HCC) and those with end-stage liver disease needing liver transplantation.

After earning his undergraduate degree from Johns Hopkins University and MD degree from UCSF, he completed residency at the Hospital of the University of Pennsylvania and both gastroenterology and advanced/transplant hepatology fellowships at UCSF. Dr. Mehta is a member of the American Association for the Study of Liver Diseases and board-certified by the American Board of Internal Medicine in Internal medicine, Gastroenterology, and Transplant Hepatology.

Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

  • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
  • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

MOST RECENT PUBLICATIONS FROM A TOTAL OF 134
Data provided by UCSF Profiles, powered by CTSI
  1. Kwong A, Hameed B, Syed S, Ho R, Mard H, Arshad S, Ho I, Suleman T, Yao F, Mehta N. Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma. Cancer Med. 2022 Jan 14. View in PubMed
  2. Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma. Liver Transpl. 2021 Dec 20. View in PubMed
  3. Kwong AJ, Ghaziani TT, Mehta N. Decreased urgency among liver transplant candidates with hepatocellular carcinoma in the United States. Liver Transpl. 2021 Nov 22. View in PubMed
  4. Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling A, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2021 Nov 15. View in PubMed
  5. Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N. The Impact of Median MELD at Transplant minus 3 national policy on waitlist outcomes in patients with and without hepatocellular carcinoma. Liver Transpl. 2021 Nov 11. View in PubMed
  6. View All Publications

 

Site Directory
    X